Prospective, Randomized, Pharmacological Intervention Study; Evaluating Effect of the Angiotensin II-receptor (AT1) Blocker Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity in Patients Treated With Trastuzumab.

Trial Profile

Prospective, Randomized, Pharmacological Intervention Study; Evaluating Effect of the Angiotensin II-receptor (AT1) Blocker Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity in Patients Treated With Trastuzumab.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2014

At a glance

  • Drugs Candesartan cilexetil (Primary)
  • Indications Cardiovascular disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Mar 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 29 Jul 2010 Additional trial location (USA) identified as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Company added as trial sponsor [Roche] as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top